Parse Biosciences
Seattle
About Parse Biosciences
Parse Bio is a biotechnology startup company developing single-cell sequencing kit solutions for researchers. By using combinatorial cDNA barcoding within cells themselves, Parse Biosciences’s technology allows researchers to eliminate the need for complex and expensive microfluidic instruments. Additionally, the company’s technology enables samples to be fixed, frozen, and stored, allowing researchers to separate out the sample extraction from downstream library preparation steps. This capability empowers researchers to run fixed samples collected on different dates together in a single experiment, providing greater control over sample handling and reducing handling errors. Split Biosciences rebranded as Parse Biosciences in 2020. The Seattle, Washington-based biotech company was established in 2018 by Alex Rosenberg, Charlie Roco, and Georg Friedrich Seelig.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $100.0M
- Funding stage: M&A
- Last round: Series C (Dec 2023)
- Website: parsebiosciences.com
- Phone: [email protected]
Industries & Categories
Bioinformatics, Biotechnology, Genetics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/parse-biosciences-23520 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.